



RECEIVED  
JUN 13 2003  
TECH CENTER 1600/2900

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q58461

Hans Berg ANDREASEN, et al.

Appln. No.: 09/509,681

Group Art Unit: 1615

Confirmation No.: 3146

Examiner: Todd Ware

Filed: March 30, 2000

For: A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND,  
IRON-DEXTRAN COMPOUND PRODUCED ACCORDING TO SAID PROCESS,  
PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF  
IRON-DEFICIENCY AND USE OF SAID COMPOUND FOR THE .....

**EXCESS CLAIM FEE PAYMENT LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Amendment Under 37 C.F.R. § 1.111 is attached hereto for concurrent filing in the above-identified application. The resulting excess claim fee has been calculated as shown below:

	After Amendment		Highest No. Previously Paid For					
All Claims	<u>33</u>	-	<u>20</u>	=	<u>13</u>	X	<u>\$18.00</u>	= <u>\$180.00</u>
Independent	<u>2</u>	-	<u>3</u>	=		X	<u>\$84.00</u>	= <u>\$0.00</u>
<b>TOTAL</b>							<b>= <u>\$234.00</u></b>	

A check for the statutory fee of \$234.00 is attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to

EXCESS CLAIM FEE PAYMENT  
U.S. Application No.: 09/509,681

Our Ref.: Q58461  
Art Unit: 1,615

Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this letter is enclosed.

Respectfully submitted,



Terrance J. Wikberg  
Registration No. 47,177

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE



23373

PATENT TRADEMARK OFFICE

Date: June 11, 2003



RECEIVED

JUN 13 2003

PATENT APPLICATION CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q58461

Hans Berg ANDREASEN, et al.

Appln. No.: 09/509,681

Group Art Unit: 1615

Confirmation No.: 3146

Examiner: Todd Ware

Filed: March 30, 2000

For: A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND,  
IRON-DEXTRAN COMPOUND PRODUCED ACCORDING TO SAID PROCESS,  
PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF  
IRON-DEFICIENCY AND USE OF SAID COMPOUND FOR THE .....

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated April 3, 2003, please amend the above-identified application as follows:

IN THE CLAIMS:

Please enter the following amended claims:

3. (Twice Amended) A process according to claim 1, characterized in that after the hydrolysis, but before being combined with the water-soluble ferric salt, the dextran is purified by one or more membrane separations having a cut-off value suitable for holding back dextran molecules above 2,700 Da.

06/12/03 SDENB01 00000033 09509681

01 FC:1202

234.00 OP